View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 11, 2019updated 12 Jul 2022 12:23pm

VirTrial enables virtual trials at Pratia site network

Clinical trials technology provider VirTrial has formed an alliance to enable virtual clinical trials at Pratia clinical research centres in Europe.

Clinical trials technology provider VirTrial has formed an alliance to enable virtual clinical trials at Pratia clinical research centres in Europe.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

All Pratia sites have undergone VirTrial’s Virtual Trial Capable training, becoming the first Virtual Trial Capable site network in Europe.

The training programme comprises four modules that must be completed by clinical research professionals for competency in general telemedicine etiquette and guidelines, and use of the VirTrial platform.

VirTrial added that participants who complete the training will be prepared to perform hybrid decentralised clinical trials (DCT).

Pratia managing director Małgorzata Gerjatowicz-Osmańska said: “Embracing telehealth technologies that enable a larger patient population to participate supports our goal and we’re proud to be the first network in Europe to offer this benefit to sponsors.

“Our network is expanding across Europe and we plan to maintain our 100% Virtual Trial Capable status with VirTrial to best serve our patients and pharma sponsors.”

VirTrial offers a telehealth platform, which provides a virtual care management (VCM) programme combining video, text, and email to allow organisations to create patient-centric trials via the replacement of certain study visits with virtual visits.

The VCM programme can be used to review and assess patient compliance and is ideal for Phase III/Phase IV trials where compliance can be evaluated from any location.

VirTrial business development vice-president Amanda Rangel said: “The innovative VirTrial telehealth platform was developed by clinical research professionals and we are committed to continued collaboration with sites and supporting site sustainability in the new era of hybrid decentralised trials.”

VirTrial recently received a hybrid decentralised clinical trial (DCT) with Hope Biosciences. The trial protocol includes remote visits through VirTrial’s telehealth platform.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena